Intelligence Feed event · Equity · 2026-10-01

    Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes Cohort

    Question

    Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes Cohort

    Direct answer

    Boehringer Ingelheim, alongside partner Zealand Pharma, published primary efficacy data from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in individuals with obesity and type 2 diabetes. Patients receiving the glucagon/GLP-1 receptor dual agonist achieved up to 13.1% body weight loss at 76 weeks compared to 3.1% in the placebo cohort. The trial also established statistically significant improvements in HbA1c glycemic markers, providing key regulatory clinical endpoints required for worldwide metabolic filing submissions.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes Cohort”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-phase-iii-trial-achieves-up-to-13-1-weight-loss-in-diabetes-cohort-ae08d8

    EQUITY
    Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes Cohort
    Boehringer Ingelheim, alongside partner Zealand Pharma, published primary efficacy data from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in individuals with obesity and type 2 diabetes. Patients receiving the glucagon/GLP-1 receptor dual agonist achieved up to 13.1% body weight loss at 76 weeks compared to 3.1% in the placebo cohort. The trial also established statistically significant improvements in HbA1c glycemic markers, providing key regulatory clinical endpoints required for worldwide metabolic filing submissions.
    ZLDPY
    Impact
    81
    OCT 1
    SIG
    90%
    ZLDPY
    Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes Cohort
    Boehringer Ingelheim, alongside partner Zealand Pharma, published primary efficacy data from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in individuals with obesity and type 2 diabetes. Patients receiving the glucagon/GLP-1 receptor dual agonist achieved up to 13.1% body weight loss at 76 weeks compared to 3.1% in the placebo cohort. The trial also established statistically significant improvements in HbA1c glycemic markers, providing key regulatory clinical endpoints required for worldwide metabolic filing submissions.
    → Positive Phase III efficacy data enhances royalty and commercial milestone realization probabilities for Zealand Pharma in the global obesity and metabolic therapeutic market.
    Impact
    Boehringer Ingelheim, alongside partner Zealand Pharma, published primary efficacy data from the Phase III SYNCHRONIZE-2 trial evaluating survodutide in individuals with obesity and type 2 diabetes. Patients receiving the glucagon/GLP-1 receptor dual agonist achieved up to 13.1% body weight loss at 76 weeks compared to 3.1% in the placebo cohort. The trial also established statistically significant improvements in HbA1c glycemic markers, providing key regulatory clinical endpoints required for worldwide metabolic filing submissions.
    Affected
    ZLDPY
    Transmission
    Positive Phase III efficacy data enhances royalty and commercial milestone realization probabilities for Zealand Pharma in the global obesity and metabolic therapeutic market.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYmilestone and future royalty cash flow accretion from Phase III validationUp1-5dZealand Pharma co-developed survodutide alongside Boehringer Ingelheim.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month